Autoimmune Disease


Results from SOBI’S Pivotal Phase 2/3 Study of Emapalumab in Patients with Primary HLH Published in New England Journal of Medicine

SOBI announced that the results from the pivotal phase 2/3 study evaluating the efficacy and safety of emapalumab in patients with primary hemophagocytic lymphohistiocytosis (HLH) were published in the New England Journal of Medicine on 7 May 2020. Emapalumab is the...

Pin It on Pinterest